Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung
Open Access
- 21 December 2006
- Vol. 109 (3), 581-587
- https://doi.org/10.1002/cncr.22413
Abstract
BACKGROUND. Adenosquamous carcinoma of the lung is composed of adenocarcinomatous and squamous cell carcinomatous components. The epidermal growth factor receptor (EGFR) mutations occur mostly in adenocarcinomas and rarely in squamous cell carcinoma of lung. Attempts to investigate the EGFR mutation status in each component of adenosquamous carcinoma and to characterize the patients according to mutation status may help to understand the histogenesis of adenosquamous carcinoma. METHODS. The mutation status of EGFR kinase domain from exon 18 to 21 was investigated in 25 Korean patients with adenosquamous carcinoma by polymerase chain reaction–single strand conformation polymorphism using the tissues of each component from the adenosquamous carcinoma tumor. Clinicopathologic characteristics of the patients according to the status of EGFR mutations were compared. RESULTS. EGFR mutations were identified in 11 (44%) patients: 9 mutations were in exon 19, 1 in exon 20, and 1 in exon 21. EGFR mutations were significantly more frequent (P = .005) in women (n = 8, 80%) than men (n = 3, 20%). Never-smokers (n = 8, 62%) had EGFR mutations more commonly than smokers (n = 3, 25%; P = .111). Identical EGFR mutations in both components of adenosquamous carcinoma were confirmed by nucleotide sequencing. CONCLUSIONS. The frequency of EGFR mutation and clinicopathologic characteristics of the EGFR mutants in adenosquamous carcinoma are similar to those of Asian patients with adenocarcinomas. Identical EGFR mutations in both components suggest the possibility of monoclonality in the histogenesis of adenosquamous carcinoma. Cancer 2007;109:581–587. © 2006 American Cancer Society.Keywords
This publication has 34 references indexed in Scilit:
- Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With ErlotinibJournal of Clinical Oncology, 2005
- Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With GefitinibJournal of Clinical Oncology, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on PrognosisJournal of Clinical Oncology, 2003
- Transition from Squamous Cell Carcinoma to Adenocarcinoma in Adenosquamous Carcinoma of the LungThe American Journal of Pathology, 2000
- KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal TumorsThe American Journal of Pathology, 2000
- Clonal Analysis of Adenosquamous Carcinoma of the LungJapanese Journal of Cancer Research, 1999
- The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survivalBritish Journal of Cancer, 1993
- Adenosquamous Carcinoma of the Lung: Clinicopathologic and Immunohistochemical FeaturesAmerican Journal of Clinical Pathology, 1992